June 8, 2023 02:21 PM EDT

Q2 deal activity points to potential 'bumper year' for pharma — report

Nicole DeFeudis

Editor

High-dollar deals in the second quarter and hungry pharmas looking to fill gaps in their pipelines are “raising hopes for a bumper year,” Evaluate Vantage …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Q2 deal activity points to potential 'bumper year' for pharma — report

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Q2 deal ac­tiv­i­ty points to po­ten­tial 'bumper year' for phar­ma — re­port

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Q2 deal activity points to potential 'bumper year' for pharma — report